{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:17:00Z","timestamp":1788448620130,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018275","name":"American Association of Hip and Knee Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009283","name":"Orthopaedic Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Orthopedic Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ocl.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:40:25Z","timestamp":1782333625000},"page":"277-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoarthritis as a Whole-Joint Disease, Part I: Current Standard of Care and Structural Therapeutic Targets in Cartilage, Synovium, and Subchondral Bone"],"prefix":"10.1016","volume":"57","author":[{"given":"Shlok V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Derwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel S.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas S.","family":"Piuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7812\/TPP\/17-084","article-title":"Hip osteoarthritis: a primer","volume":"22","author":"Lespasio","year":"2018","journal-title":"Perm J"},{"key":"10.1016\/j.ocl.2026.05.001_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7812\/TPP\/16-183","article-title":"Knee osteoarthritis: a primer","volume":"21","author":"Lespasio","year":"2017","journal-title":"Perm J"},{"issue":"24","key":"10.1016\/j.ocl.2026.05.001_bib3","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1001\/jama.2016.16885","article-title":"US spending on personal health care and public health, 1996-2013","volume":"316","author":"Dieleman","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.001_bib4","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.001_bib5","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/art.34453","article-title":"Osteoarthritis: a disease of the joint as an organ","volume":"64","author":"Loeser","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10182","key":"10.1016\/j.ocl.2026.05.001_bib6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.001_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s12276-021-00710-y","article-title":"Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions","volume":"53","author":"Cho","year":"2021","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/acr.24131","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee","volume":"72","author":"Kolasinski","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ocl.2026.05.001_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2019.02.037","article-title":"Osteoarthritis phenotypes and novel therapeutic targets","volume":"165","author":"Van Spil","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020355","article-title":"Advances and challenges in the pursuit of disease-modifying osteoarthritis drugs: a review of 2010\u20132024 clinical trials","volume":"13","author":"Brandt","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/19476035221074003","article-title":"Assessment of clinical, tissue, and cell-level metrics identify four biologically distinct knee osteoarthritis patient phenotypes","volume":"13","author":"Mantripragada","year":"2022","journal-title":"Cartilage"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.001_bib12","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.5435\/JAAOS-D-21-01233","article-title":"AAOS Clinical Practice Guideline summary: management of osteoarthritis of the knee (Nonarthroplasty), third edition","volume":"30","author":"Brophy","year":"2022","journal-title":"J Am Acad Orthop Surg"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.001_bib13","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"Bannuru","year":"2019","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.ocl.2026.05.001_bib14","series-title":"Osteoarthritis in over 16s: diagnosis and management [Internet]","year":"2022"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/rai2.12018","article-title":"Inflammatory phenotype of osteoarthritis and its potential therapies","volume":"1","author":"Cao","year":"2021","journal-title":"Rheumatol Autoimmun"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.semarthrit.2021.03.005","article-title":"The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial","volume":"51","author":"Guehring","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"14","key":"10.1016\/j.ocl.2026.05.001_bib17","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2019.14735","article-title":"Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis","volume":"322","author":"Hochberg","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00441-011-1194-6","article-title":"Age-dependent alteration of TGF-\u03b2 signalling in osteoarthritis","volume":"347","author":"van der Kraan","year":"2012","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2022.100238","article-title":"Inhibition of transforming growth factor-\u03b2 in osteoarthritis. Discrepancy with reduced TGF\u03b2 signaling in normal joints","volume":"4","author":"van der Kraan","year":"2022","journal-title":"Osteoarthr Cartil Open"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1089\/humc.2017.249","article-title":"A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients","volume":"29","author":"Kim","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12891-017-1830-8","article-title":"Structural effects of intra-articular TGF-\u03b21 in moderate to advanced knee osteoarthritis: MRI-based assessment in a randomized controlled trial","volume":"18","author":"Guermazi","year":"2017","journal-title":"BMC Muscoskelet Disord"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0038-1676803","article-title":"Results of a phase II study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-\u03b21","volume":"33","author":"Lee","year":"2020","journal-title":"J Knee Surg"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.001_bib23","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/13543784.2018.1539075","article-title":"Investigational drugs for the treatment of osteoarthritis, an update on recent developments","volume":"27","author":"Zhu","year":"2018","journal-title":"Expert Opin Invest Drugs"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.001_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/ar2521","article-title":"Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression","volume":"10","author":"Hayashi","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ocl.2026.05.001_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1471-2474-11-232","article-title":"Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis","volume":"11","author":"Hunter","year":"2010","journal-title":"BMC Muscoskelet Disord"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.001_bib26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","article-title":"A phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis","volume":"29","author":"Yazici","year":"2021","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"10.1016\/j.ocl.2026.05.001_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96308","article-title":"Inhibition of Wnt\/\u03b2-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis","volume":"3","author":"Lietman","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ocl.2026.05.001_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221090297","article-title":"Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)","volume":"14","author":"Oo","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1042\/BJ20151072","article-title":"Anti-ADAMTS5 monoclonal antibodies: implications for aggrecanase inhibition in osteoarthritis","volume":"473","author":"Apte","year":"2016","journal-title":"Biochem J"},{"issue":"33","key":"10.1016\/j.ocl.2026.05.001_bib30","doi-asserted-by":"crossref","first-page":"23443","DOI":"10.1074\/jbc.274.33.23443","article-title":"Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family","volume":"274","author":"Abbaszade","year":"1999","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.joca.2024.09.002","article-title":"Degradomics defines proteolysis information flow from human knee osteoarthritis cartilage to matched synovial fluid and the contributions of secreted proteases ADAMTS5, MMP13 and CMA1 to articular cartilage breakdown","volume":"33","author":"Bhutada","year":"2025","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.001_bib32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.joca.2023.04.001","article-title":"Evaluation of S201086\/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial","volume":"31","author":"Schnitzer","year":"2023","journal-title":"Osteoarthr Cartil"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/ar2315","article-title":"Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study","volume":"9","author":"Krzeski","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"10.1016\/j.ocl.2026.05.001_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311098","article-title":"Identification of N-Acyl hydrazones as new non-zinc-binding MMP-13 inhibitors by structure-based virtual screening studies and chemical optimization","volume":"24","author":"Cuffaro","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ocl.2026.05.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113666","article-title":"Development of a selective matrix metalloproteinase 13 (MMP-13) inhibitor for the treatment of osteoarthritis","volume":"224","author":"Bendele","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"22","key":"10.1016\/j.ocl.2026.05.001_bib36","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1039\/D3TB02871B","article-title":"On-demand release of a selective MMP-13 blocker from an enzyme-responsive injectable hydrogel protects cartilage from degenerative progression in osteoarthritis","volume":"12","author":"Roy","year":"2024","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ocl.2026.05.001_bib37","article-title":"Update on novel non-operative treatment for osteoarthritis: current status and future trends","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-021-02622-8","article-title":"Study TPX-100-5: intra-articular TPX-100 significantly delays pathological bone shape change and stabilizes cartilage in moderate to severe bilateral knee OA","volume":"23","author":"McGuire","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ostima.2024.100178","article-title":"3-dimensional bone shape and knee osteoarthritis: what have we learned?","volume":"4","author":"Brett","year":"2024","journal-title":"Osteoarthr Imaging"},{"key":"10.1016\/j.ocl.2026.05.001_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.645842","article-title":"New trends in pharmacological treatments for osteoarthritis","volume":"12","author":"Cai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ocl.2026.05.001_bib41","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22115.1","article-title":"Recent advances in the treatment of osteoarthritis","volume":"9","author":"Gr\u00e4ssel","year":"2020","journal-title":"F1000Res"},{"issue":"19","key":"10.1016\/j.ocl.2026.05.001_bib42","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.2017.5283","article-title":"Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial","volume":"317","author":"McAlindon","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.001_bib43","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.joca.2017.09.007","article-title":"Safety, tolerability, and pharmacodynamics of an anti-interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study","volume":"25","author":"Wang","year":"2017","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.001_bib44","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40840","article-title":"A phase II trial of Lutikizumab, an Anti-Interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.001_bib45","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T","article-title":"Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.001_bib46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/ard.2008.088732","article-title":"Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI","volume":"68","author":"Raynauld","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11926-008-0008-7","article-title":"Licofelone: the answer to unmet needs in osteoarthritis therapy?","volume":"10","author":"Kulkarni","year":"2008","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.001_bib48","doi-asserted-by":"crossref","first-page":"R1091","DOI":"10.1186\/ar1788","article-title":"The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases","volume":"7","author":"Pelletier","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/annrheumdis-2012-202239","article-title":"A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee","volume":"72","author":"Hellio le Graverand","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.joca.2016.08.010","article-title":"I\u03baB kinase inhibition as a potential treatment of osteoarthritis - results of a clinical proof-of-concept study","volume":"25","author":"Grothe","year":"2017","journal-title":"Osteoarthr Cartil"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.001_bib51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3349\/ymj.2015.56.5.1379","article-title":"Efficacy of direct injection of etanercept into knee joints for pain in moderate and severe knee osteoarthritis","volume":"56","author":"Ohtori","year":"2015","journal-title":"Yonsei Med J"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.001_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0300060517723182","article-title":"Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: an open-label randomized controlled trial","volume":"46","author":"Wang","year":"2018","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.ocl.2026.05.001_bib53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.001_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M20-0527","article-title":"Effects of Interleukin-1\u03b2 inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial","volume":"173","author":"Schieker","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.001_bib55","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/jamainternmed.2025.1359","article-title":"Low-dose methotrexate for the treatment of inflammatory knee osteoarthritis: a randomized clinical trial","volume":"185","author":"Zhu","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.001_bib56","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.7326\/M24-0303","article-title":"Pain reduction with oral methotrexate in knee osteoarthritis : a randomized, placebo-controlled clinical trial","volume":"177","author":"Kingsbury","year":"2024","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.001_bib57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1055\/s-0039-1677792","article-title":"Are subchondral intraosseous injections effective and safe for the treatment of knee osteoarthritis? A systematic review","volume":"32","author":"Sundaram","year":"2019","journal-title":"J Knee Surg"},{"issue":"15","key":"10.1016\/j.ocl.2026.05.001_bib58","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2020.2938","article-title":"Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial","volume":"323","author":"Cai","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ocl.2026.05.001_bib59","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","article-title":"Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial","volume":"71","author":"Laslett","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ocl.2026.05.001_bib60","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/rheumatology\/kev123","article-title":"Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study","volume":"54","author":"Varenna","year":"2015","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.001_bib61","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s10067-013-2338-8","article-title":"Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial","volume":"32","author":"Nishii","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib62","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.joca.2017.11.013","article-title":"Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials","volume":"26","author":"Vaysbrot","year":"2018","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/M19-0675","article-title":"Disease-modifying effects of a novel cathepsin k inhibitor in osteoarthritis: a randomized controlled trial","volume":"172","author":"Conaghan","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ocl.2026.05.001_bib64","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","article-title":"Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials","volume":"23","author":"Karsdal","year":"2015","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2012-202231","article-title":"Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial","volume":"72","author":"Reginster","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.001_bib66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/annrheumdis-2013-203989","article-title":"Disease-modifying effect of strontium ranelate in a subset of patients from the phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss","volume":"74","author":"Pelletier","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.001_bib67","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1517\/14740338.2014.939169","article-title":"Cardiac concerns associated with strontium ranelate","volume":"13","author":"Reginster","year":"2014","journal-title":"Expert Opin Drug Saf"}],"container-title":["Orthopedic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589826000714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589826000714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:30:52Z","timestamp":1788445852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030589826000714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0030589826000714"],"URL":"https:\/\/doi.org\/10.1016\/j.ocl.2026.05.001","relation":{},"ISSN":["0030-5898"],"issn-type":[{"value":"0030-5898","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoarthritis as a Whole-Joint Disease, Part I: Current Standard of Care and Structural Therapeutic Targets in Cartilage, Synovium, and Subchondral Bone","name":"articletitle","label":"Article Title"},{"value":"Orthopedic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocl.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}